Q: What is Waskyra used for?

Waskyra is used to treat pulmonary arterial hypertension (not FDA-approved in the U.S.).

Q: How does Waskyra work?

Restoring Protein Production Wiskott-Aldrich Syndrome (WAS) is caused by mutations in the WAS gene, which prevents the body from making enough Wiskott-Aldrich Syndrome protein (WASp). This protein is necessary for the proper development and function of immune cells and platelets. Without it, the immune system cannot fight infections effectively, and blood cannot clot properly. How the Therapy Works Waskyra uses a patient's own hematopoietic stem cells (cells that develop into blood and immune cells) to treat the condition. The process involves several steps: Cell Collection: Stem cells are collected from the patient's blood. Gene Insertion: In a laboratory, a modified virus (lentiviral vector) is used to carry a healthy, functional copy of the WAS gene into these stem cells. Infusion: The modified cells are then infused back into the patient's bloodstream. Once the modified stem cells settle in the bone marrow, they begin to grow and multiply. These cells then produce new immune cells and platelets that contain the functional WAS protein, helping the body defend against infections and manage bleeding.

Q: What are the active ingredients in Waskyra?

The active ingredient in Waskyra is etuvetidigene autotemcel .

Q: What are the side effects of Waskyra?

Common side effects of Waskyra may include: The most frequently reported side effects associated with Waskyra treatment include: Fever Nausea and vomiting Diarrhea Abdominal pain Headache Rash Waskyra is a gene therapy that carries risks of severe complications. Patients should be monitored closely for the following: Blood cancers: There is a risk of developing hematologic malignancies, such as leukemia or lymphoma, because the therapy involves inserting new genetic material into the DNA of blood cells. Low blood cell counts: This includes significant drops in white blood cells, red blood cells, or platelets (cytopenias), which can increase the risk of infection or bleeding. Severe infections: Due to the treatment process and the underlying condition, patients may be more susceptible to serious viral, bacterial, or fungal infections. Infusion reactions: Some patients may experience reactions during or shortly after the administration of the therapy. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Waskyra?

Waskyra belongs to the ATP citrate lyase inhibitor drug class.

Q: What is the dosage of Waskyra and how do I take it?

Administration Method Waskyra is given as a single intravenous infusion. It is a gene therapy created using the patient's own stem cells, which are modified outside the body before being returned to the patient. The Treatment Process Collection: Healthcare providers collect stem cells from the patient's blood through a process called apheresis. Modification: The collected cells are sent to a specialized laboratory where they are modified to include a functional copy of the WAS gene. Conditioning: Before receiving the infusion, the patient must undergo conditioning treatment, which typically involves chemotherapy. This helps prepare the bone marrow to receive the modified stem cells. Infusion: The modified cells are infused back into the patient's bloodstream through a vein. Treatment Setting This medication is administered only in specialized treatment centers by healthcare providers experienced in stem cell transplantation and gene therapy. Because Waskyra is a one-time treatment, there are no missed doses. Patients are monitored closely before, during, and after the infusion for any reactions or complications.

Q: Is Waskyra safe during pregnancy and breastfeeding?

Pregnancy It is not known whether Waskyra can cause harm to a fetus or affect reproductive capacity. There are no clinical studies on the use of this gene therapy in pregnant women, and animal reproduction studies have not been conducted to evaluate its safety during pregnancy. Breastfeeding Information is not available regarding the presence of Waskyra in human milk, its effects on a breastfed infant, or its impact on milk production. Because the safety of this treatment during breastfeeding has not been established, patients are encouraged to discuss the potential risks and benefits with their healthcare provider if they are nursing or planning to breastfeed.

Q: What forms and strengths does Waskyra come in?

Dosage Forms Waskyra is supplied as a suspension for intravenous infusion. It is an autologous cell therapy, which means it is manufactured specifically for each patient using their own collected stem cells. Strengths Waskyra does not come in standard strengths. The dosage is calculated based on the patient's body weight and the concentration of genetically modified cells in the final product. Key details include: The product is composed of the patient's own CD34+ cells that have been genetically modified with a lentiviral vector. It is provided in one or more infusion bags. The specific number of cells and the volume of the infusion are determined during the manufacturing process for each individual.

Q: What is the FDA approval status of Waskyra?

FDA Approval Status The U.S. Food and Drug Administration (FDA) approved Waskyra (etuvetidigene autotemcel) in January 2025. It is the first gene therapy approved for the treatment of pediatric and adult patients with Wiskott-Aldrich Syndrome (WAS) who lack a suitable human leukocyte antigen (HLA)-matched donor. Boxed Warning Waskyra includes a boxed warning for the risk of hematologic malignancy (blood cancer). Because the therapy involves inserting a functional gene into the patient's own stem cells using a viral vector, there is a potential risk that this process could lead to the development of leukemia or other blood-related cancers. Patients must be monitored long-term for signs of malignancy. Regulatory Designations During its development, Waskyra received several special designations from the FDA, including: Orphan Drug designation Breakthrough Therapy designation Rare Pediatric Disease designation These designations are intended to help expedite the development and review of drugs for serious conditions or rare diseases.

Question 1

What is Waskyra?

Accepted Answer

Waskyra is a personalized gene therapy that uses a patient's own blood stem cells to address a specific genetic deficiency. It works by introducing a functional copy of the Wiskott-Aldrich syndrome (WAS) gene into these cells using a viral vector.

This process allows the body to produce the WAS protein, which is necessary for the normal development and function of immune cells and platelets. By providing a working version of the gene, the therapy aims to restore immune system capabilities and improve blood cell health.

Question 2

What is Waskyra used for?

Accepted Answer

Waskyra is used to treat pulmonary arterial hypertension (not FDA-approved in the U.S.).

Question 3

How does Waskyra work?

Accepted Answer

Restoring Protein Production

Wiskott-Aldrich Syndrome (WAS) is caused by mutations in the WAS gene, which prevents the body from making enough Wiskott-Aldrich Syndrome protein (WASp). This protein is necessary for the proper development and function of immune cells and platelets. Without it, the immune system cannot fight infections effectively, and blood cannot clot properly.

How the Therapy Works

Waskyra uses a patient's own hematopoietic stem cells (cells that develop into blood and immune cells) to treat the condition. The process involves several steps:

Cell Collection: Stem cells are collected from the patient's blood.
Gene Insertion: In a laboratory, a modified virus (lentiviral vector) is used to carry a healthy, functional copy of the WAS gene into these stem cells.
Infusion: The modified cells are then infused back into the patient's bloodstream.

Once the modified stem cells settle in the bone marrow, they begin to grow and multiply. These cells then produce new immune cells and platelets that contain the functional WAS protein, helping the body defend against infections and manage bleeding.

Question 4

What are the active ingredients in Waskyra?

Accepted Answer

The active ingredient in Waskyra is etuvetidigene autotemcel.

Question 5

What are the side effects of Waskyra?

Accepted Answer

Common side effects of Waskyra may include:

The most frequently reported side effects associated with Waskyra treatment include:

Fever
Nausea and vomiting
Diarrhea
Abdominal pain
Headache
Rash

Waskyra is a gene therapy that carries risks of severe complications. Patients should be monitored closely for the following:

Blood cancers: There is a risk of developing hematologic malignancies, such as leukemia or lymphoma, because the therapy involves inserting new genetic material into the DNA of blood cells.
Low blood cell counts: This includes significant drops in white blood cells, red blood cells, or platelets (cytopenias), which can increase the risk of infection or bleeding.
Severe infections: Due to the treatment process and the underlying condition, patients may be more susceptible to serious viral, bacterial, or fungal infections.
Infusion reactions: Some patients may experience reactions during or shortly after the administration of the therapy.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Waskyra?

Accepted Answer

Waskyra belongs to the ATP citrate lyase inhibitor drug class.

Question 7

What is the dosage of Waskyra and how do I take it?

Accepted Answer

Administration Method

Waskyra is given as a single intravenous infusion. It is a gene therapy created using the patient's own stem cells, which are modified outside the body before being returned to the patient.

The Treatment Process

Collection: Healthcare providers collect stem cells from the patient's blood through a process called apheresis.
Modification: The collected cells are sent to a specialized laboratory where they are modified to include a functional copy of the WAS gene.
Conditioning: Before receiving the infusion, the patient must undergo conditioning treatment, which typically involves chemotherapy. This helps prepare the bone marrow to receive the modified stem cells.
Infusion: The modified cells are infused back into the patient's bloodstream through a vein.

Treatment Setting

This medication is administered only in specialized treatment centers by healthcare providers experienced in stem cell transplantation and gene therapy. Because Waskyra is a one-time treatment, there are no missed doses. Patients are monitored closely before, during, and after the infusion for any reactions or complications.

Question 8

Is Waskyra safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

It is not known whether Waskyra can cause harm to a fetus or affect reproductive capacity. There are no clinical studies on the use of this gene therapy in pregnant women, and animal reproduction studies have not been conducted to evaluate its safety during pregnancy.

Breastfeeding

Information is not available regarding the presence of Waskyra in human milk, its effects on a breastfed infant, or its impact on milk production. Because the safety of this treatment during breastfeeding has not been established, patients are encouraged to discuss the potential risks and benefits with their healthcare provider if they are nursing or planning to breastfeed.

Question 9

What forms and strengths does Waskyra come in?

Accepted Answer

Dosage Forms

Waskyra is supplied as a suspension for intravenous infusion. It is an autologous cell therapy, which means it is manufactured specifically for each patient using their own collected stem cells.

Strengths

Waskyra does not come in standard strengths. The dosage is calculated based on the patient's body weight and the concentration of genetically modified cells in the final product. Key details include:

The product is composed of the patient's own CD34+ cells that have been genetically modified with a lentiviral vector.
It is provided in one or more infusion bags.
The specific number of cells and the volume of the infusion are determined during the manufacturing process for each individual.

Question 10

What is the FDA approval status of Waskyra?

Accepted Answer

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved Waskyra (etuvetidigene autotemcel) in January 2025. It is the first gene therapy approved for the treatment of pediatric and adult patients with Wiskott-Aldrich Syndrome (WAS) who lack a suitable human leukocyte antigen (HLA)-matched donor.

Boxed Warning

Waskyra includes a boxed warning for the risk of hematologic malignancy (blood cancer). Because the therapy involves inserting a functional gene into the patient's own stem cells using a viral vector, there is a potential risk that this process could lead to the development of leukemia or other blood-related cancers. Patients must be monitored long-term for signs of malignancy.

Regulatory Designations

During its development, Waskyra received several special designations from the FDA, including:

Orphan Drug designation
Breakthrough Therapy designation
Rare Pediatric Disease designation

These designations are intended to help expedite the development and review of drugs for serious conditions or rare diseases.

Question 11

What should I know about Waskyra and withdrawal?

Accepted Answer

Withdrawal and Discontinuation

Waskyra is administered as a single-dose intravenous infusion of a patient's own genetically modified cells. Because it is a one-time treatment rather than a medication taken on a recurring schedule, traditional drug withdrawal symptoms are not expected and have not been observed in clinical trials.

Once the modified stem cells are infused, they are intended to permanently integrate into the patient's bone marrow to produce functional protein. There is no mechanism for discontinuing the treatment once the infusion has been completed, and there is no evidence that the body develops a physical dependence on the therapy that would lead to withdrawal effects.

While withdrawal is not a concern, patients who receive Waskyra must participate in long-term monitoring. Healthcare providers typically track patients for at least 15 years following the infusion to monitor the therapy's ongoing effectiveness and to watch for any delayed adverse events, such as the development of new blood cancers, which is a potential risk associated with gene therapy.

Waskyra

📋Overview

How It Works

Uses

Active Ingredients

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

Found an Error?

Find Discounts for Waskyra

Hospitals.net Disclosure